Five Prime Therapeutics, Inc.Product Pipeline Review - 2015
Summary
Global Markets Directs, Five Prime Therapeutics, Inc.Product Pipeline Review - 2015, provides an overview of the Five Prime Therapeutics, Inc.s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Five Prime Therapeutics, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides brief overview of Five Prime Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of Five Prime Therapeutics, Inc.s human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement
Latest news and deals relating to the Five Prime Therapeutics, Inc.s pipeline products
Reasons to buy
Evaluate Five Prime Therapeutics, Inc.s strategic position with total access to detailed information on its product pipeline
Assess the growth potential of Five Prime Therapeutics, Inc. in its therapy areas of focus
Identify new drug targets and therapeutic classes in the Five Prime Therapeutics, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of Five Prime Therapeutics, Inc. and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of Five Prime Therapeutics, Inc.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Explore the dormant and discontinued projects of Five Prime Therapeutics, Inc. and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues
Table of Contents
List of Tables 4
List of Figures 4
Five Prime Therapeutics, Inc. Snapshot 5
Five Prime Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Five Prime Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Five Prime Therapeutics, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Five Prime Therapeutics, Inc. - Pipeline Products Glance 14
Five Prime Therapeutics, Inc. - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Five Prime Therapeutics, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Five Prime Therapeutics, Inc. - Drug Profiles 17
FPA-008 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
FP-1039 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
FPA-144 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
INBRX-110 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclonal Antibodies for Cancer 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibodies for Solid Tumors 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Proteins for Asthma and Chronic Obstructive Pulmonary Disease 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Proteins for Central Nervous System Disorders 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Five Prime Therapeutics, Inc. - Pipeline Analysis 28
Five Prime Therapeutics, Inc. - Pipeline Products by Target 28
Five Prime Therapeutics, Inc. - Pipeline Products by Route of Administration 29
Five Prime Therapeutics, Inc. - Pipeline Products by Molecule Type 30
Five Prime Therapeutics, Inc. - Pipeline Products by Mechanism of Action 31
Five Prime Therapeutics, Inc. - Recent Pipeline Updates 32
Five Prime Therapeutics, Inc. - Dormant Projects 36
Five Prime Therapeutics, Inc. - Locations And Subsidiaries 37
Head Office 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39
List of Tables
Five Prime Therapeutics, Inc., Key Information 5
Five Prime Therapeutics, Inc., Key Facts 5
Five Prime Therapeutics, Inc. - Pipeline by Indication, 2015 7
Five Prime Therapeutics, Inc. - Pipeline by Stage of Development, 2015 8
Five Prime Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 9
Five Prime Therapeutics, Inc. - Partnered Products in Pipeline, 2015 10
Five Prime Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 11
Five Prime Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2015 12
Five Prime Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 13
Five Prime Therapeutics, Inc. - Phase I, 2015 14
Five Prime Therapeutics, Inc. - Preclinical, 2015 15
Five Prime Therapeutics, Inc. - Discovery, 2015 16
Five Prime Therapeutics, Inc. - Pipeline by Target, 2015 28
Five Prime Therapeutics, Inc. - Pipeline by Route of Administration, 2015 29
Five Prime Therapeutics, Inc. - Pipeline by Molecule Type, 2015 30
Five Prime Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015 31
Five Prime Therapeutics, Inc. - Recent Pipeline Updates, 2015 32
Five Prime Therapeutics, Inc. - Dormant Developmental Projects,2015 36
List of Figures
Five Prime Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015 7
Five Prime Therapeutics, Inc. - Pipeline by Stage of Development, 2015 8
Five Prime Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 9
Five Prime Therapeutics, Inc. - Partnered Products in Pipeline, 2015 10
Five Prime Therapeutics, Inc. - Pipeline by Top 10 Target, 2015 28
Five Prime Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015 30
Five Prime Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 31
